Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 16January 2023 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.
Under the programme initiated 4 November 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 7 November 2022 to 30 January 2023.
Since the announcement of the programme, the following transactions have been made:
Number of B shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 3,050,265 | 2,684,398,099 | |
9 January 2023 | 74,000 | 964.21 | 71,351,652 |
10 January 2023 | 80,000 | 932.47 | 74,597,253 |
11 January 2023 | 80,000 | 915.51 | 73,241,142 |
12 January 2023 | 80,000 | 908.42 | 72,673,892 |
13 January 2023 | 75,000 | 931.50 | 69,862,150 |
Accumulated under the programme | 3,439,265 | 3,046,124,188 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 30,868,083 B shares of DKK 0.20 as treasury shares, corresponding to 1.4% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 13 January 2023, Novo Nordisk has since 2 February 2022 repurchased a total of 29,178,897 B shares at an average share price of DKK 796.11 per B share equal to a transaction value of DKK 23,229,526,243.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 53,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn andYouTube.
Contact for further information
Media: | |
Ambre Brown Morley +45 3079 9289 abmo@novonordisk.com | Natalia SalomaoAbrahao (US) +1 848 304 1027 niaa@novonordisk.com |
Investors: | |
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
Company announcement No 02 / 2023
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
HSBC Continental Europe: Post Stabilisation Notice19.4.2024 09:30:00 CEST | Press release
PARIS, April 19, 2024 (GLOBE NEWSWIRE) -- NBN Co Limited Post Stabilisation Notice HSBC (contact: syndexecution@noexternalmail.hsbc.com) hereby gives notice that no stabilisation was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer:NBN Co LimitedGuarantor (if any):naAggregate nominal amount:EUR 700,000,000 / EUR 600,000,000Description:3.5% due 22nd March 2030 / 3.75% due 22nd March 2034Offer price:99.660 / 99.926 Stabilising Manager:HSBC Continental Europe This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of t
NEXEN Tire hosts ‘2024 Purple Summit Korea’19.4.2024 09:00:00 CEST | Press release
Carried out sixth hospitality program inviting 60 global partners and executives from around the world SEOUL, South Korea, April 19, 2024 (GLOBE NEWSWIRE) -- NEXEN Tire, a leading global tire manufacturer, today announced that it hosted the 2024 Purple Summit Korea hospitality event, which took place in Korea for the first time from April 16 to 19. The event featured 60 global partners and executives from all over the world, as well as NEXEN Tire representatives. Since 2016, NEXEN Tire has hosted the Purple Summit, an integrated hospitality and marketing program, that aims to foster and strengthen relationships while also increasing the company's global market presence. Throughout the summit, attendees visited the company’s cutting-edge tire plant located in Changnyeong, as well as The NEXEN UniverCity, NEXEN Tire’s central R&D hub. Not only that, but the tire maker invited KLPGA players from the NEXEN-St. Nine Masters event to play golf with guests and tour Busan, Korea’s second large
Fujifilm Healthcare Europe launches lifelike ESD training simulator EndoGel19.4.2024 09:00:00 CEST | Press release
RATINGEN, Germany, April 19, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Europe GmbH is pleased to announce the launch of EndoGel, a training model designed for performing Endoscopic Submucosal Dissection (ESD) and Peroral Endoscopic Myotomy (POEM) procedures. This innovative simulator, available in two versions - EndoGel for ESD and EndoGel for ESD/POEM - represents a significant advance in endoscopic training. This simulator aims to improve the skills of endoscopy professionals across Europe and ultimately improve patient outcomes. EndoGel simulates the texture of human tissue involved in ESD and POEM procedures, providing clinicians with a life-like simulation experience. With this unique and innovative training model, endoscopy professionals can benefit from the ability to - practice marking and injecting, - performing circumferential incisions, - performing submucosal dissection, myotomy and clipping. EndoGel is compatible with a wide range of medical devices used in ESD and POEM
NOTICE TO THE ANNUAL GENERAL MEETING OF QPR SOFTWARE PLC19.4.2024 09:00:00 CEST | Press release
QPR SOFTWARE PLC STOCK EXCHANGE RELEASE 19 APRIL 2024 AT 10 A.M. EET NOTICE TO THE ANNUAL GENERAL MEETING OF QPR SOFTWARE PLC Notice is hereby given to the shareholders of QPR Software Plc (“QPR” or the “Company”) that the Annual General Meeting (the “General Meeting”) will be held on Wednesday May 15, 2024, starting at 2:30 p.m. (EEST) at the Company's headquarters at Huopalahdentie 24, 00350 Helsinki, Finland. The reception of shareholders who have registered for the meeting and serving of coffee prior to the meeting will start at 2:00 p.m. (EEST). Matters on the agenda of the General Meeting Opening of the General Meeting Matters of order for the General Meeting Election of a person to scrutinize the minutes and a person to supervise the counting of votes Recording the legality of the meeting Recording the attendance at the meeting and adoption of the list of votes Presentation of the Financial Statements, the report of the Board of Directors and the Auditor’s Report for the year 20
Danske Bank A/S, ledende medarbejderes transaktioner19.4.2024 08:58:55 CEST | pressemeddelelse
19. april 2024 Indberetning nr. 39/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftet fil APMH Invest A_S - salg - 2024.04.18